## NAMIBIA MEDICINES REGULATORY COUNCIL



## MINISTRY OF HEALTH AND SOCIAL SERVICES

## FEES PAYABLE TO THE REGISTRAR

(Regulation 47)

- 1. In respect of an application for registration of a Category A medicine -
- (a) in respect of a medicine compounded in its entirety in Namibia -
- (i) for a new chemical entity, including novel dosage forms or delivery systems -

(aa) per application: N\$3000-00;

(bb) for registration: N\$1000-00;

(ii) for an interchangeable multi-source medicine -

(aa) per application: N\$1000-00;

(bb) for registration: N\$ 500-00;

(iii) for a line extension of a medicine -

(aa) per application: N\$1000-00;

(bb) for registration: N\$ 500-00;

(iv) for a medicine not referred to in subparagraphs (i), (ii), or (iii) -

(aa)	per ap	oplication:	N\$1000-00; N\$ 500-00;			
(bb)	for re	gistration:				
(v)	annually, in respect of the retention of the registration of a medicine, and this fee					
	will be payable before or on the expiry of 12 months after the date on which the					
	registration of the said medicine has been approved by					
	the Council: *		N\$ 500-00;			
	(vi)	in respect of an application for -				
	(aa)	gister (whether approved				
		or not):	N\$ 500-00;			
	(bb)	the transfer of a certificate of registr	ration (whether approved			
		or not):	N\$ 250-00;			
	(b)	in respect of a medicine, not compounded in its entirety in Namibia -				
	(i)	for a new chemical entity, including novel dosage forms or delivery				
		systems -				
	(aa)	per application:	N\$3500-00;			
	(bb)	for registration:	N\$1050-00;			
	(ii)	for an interchangeable multi-source medicine -				
	(aa)	per application:	N\$1750-00;			
	(bb)	for registration:	N\$ 700-00			
	(iii)	for a line extension of a medicine -				
	(aa)	per application:	N\$1750-00;			
	(bb)	for registration:	US\$ 700-00;			
	(iv)	for a medicine not referred to in subparagraphs (i), (ii), or (iii) -				
	(aa)	per application:	N\$1750-00;			

(bb)	for registration:	N\$ 700-00;		
(v)	annually, in respect of the <b>retention</b> of the registration of a medicine, and this fee will be payable before or on the expiry of 12 months after the date on which the registration of the said medicine has been approved by the Council:*  N\$1050-00;			
		1,41000 00,		
(vi)	in respect of an application for -			
(aa)	the amendment of an entry in the register (whether	lment of an entry in the register (whether approved		
	or not):	N\$1050-00;		
(bb)	transfer of a certificate of registration (whether app	proved		
	or not):	N\$ 700-00.		
In res <sub>]</sub> (a)	in respect of a medicine compounded in its entirety in Namibia -			
(i)	for a new chemical entity, including novel dosage forms or delivery systems -			
(aa)	per application:	N\$1500-00;		
(bb)	for registration:	N\$ 500-00;		
(ii) (aa)	for an interchangeable multi-source medicine - per application:	N\$ 500-00;		
(bb)	for registration:	N\$ 250-00;		
(iii)	for a line extension of a medicine -			

N\$ 500-00;

N\$ 250-00;

2.

per application:

for registration:

(aa)

(bb)

(iv)	for a medicine not referred to in subparagraphs (i), (ii), or (iii) -					
(aa)	per application:	N\$	500-00;			
(bb)	for registration:	N\$	250-00;			
(v)	annually, in respect of the retention of the registration of a medicine, and					
	this fee will be payable before or on the expiry of 12 months after the date					
	on which the registration of the said medicine has been approved by the					
	Council: *	N\$	250-00;			
(vi)	in respect of an application for -					
(aa)	the amendment of an entry in the register (whether approved					
	or not):	N\$	250-00;			
(bb)	the transfer of a certificate of registration (whether approved					
	or not):	N\$	125-00;			
(b)	in respect of a medicine, not compounded in its					
	entirety in Namibia –					
(i)	for a new chemical entity, including novel dosage forms or delivery					
	systems -					
(aa)	per application:	<b>N</b> \$2	2100-00;			
(bb)	for registration:	N\$	7100-00;			
(ii)	for an interchangeable multi-source	e medicine -				
(aa)	per application:	N\$	875-00;			
(bb)	for registration:	N\$	350-00			
(iii)	for a line extension of a medicine -					
(aa)	per application:	N\$	875-00;			
(bb)	for registration:	N\$	350-00;			

	(iv)	(iv) for a medicine not referred to in subparagraphs (i), (ii), or (iii) -			
	(aa)	per application:	N\$ 875-00;		
	(bb)	for registration:	N\$ 350-00;		
	(v) annually, in respect of the <b>retention</b> of the registration of a medicin				
		this fee will be payable before or on the expiry of 12 months after the date			
		on which the registration of the said medicine has been approved by the			
		Council:*	N\$ 525-00;		
	(vi)	in respect of an application for -			
	(aa) the amendment of an entry in the register (whether approved				
		or not):	N\$ 525-00;		
	(bb) transfer of a certificate of registration (whether approved		pproved		
		or not):	N\$ 350-00.		
3.	In respect of any licence issued in terms of section 31				
	of the Act:		N\$1000-00.		
4.	In res				
	unregistered medicine -				
(a)	registered outside Namibia but not registered				
	in Na	mibia	N\$4000-00;		
(b)	not re	gistered at all	N\$6000-00;		
(c)	not registered at all, but forming part of a clinical				
	trial		N\$6000-00;		
(d)	registered in Namibia, but forming part of a clinical trial for purposes of other				
	indica	ations	N\$2000-00;		
(e)	presci	ribed for a specific patient	N\$ 50-00.		
5.	In res	pect of an application for the registration of a			
		ises used for the manufacturing of medicines:	N\$1000-00.		

- 6. For the performance of an inspection to determine whether a premises referred to in item 5 are suitable to be registered as such
  - (a) in respect of the premises of a manufacturer of medicines in Namibia N\$400-00 per

(b) in respect of the premises of a manufacturer of medicines

outside Namibia

N\$9000-00 per site, plus travelling and accommodation costs for two inspectors.

hour.

## \* Please note:

- (a) The fees referred to in paragraph 1(a)(v) and (b)(v) payable during a particular calendar year must be paid on or before the last working day of March of that year, failing which the Registrar must cancel the registration of the medicines concerned as contemplated in terms of section 22(4) of the Act.
- (b) For the purposes of this Annexure "line extension of a medicine" means any additional strength to the pharmaceutical form, excluding novel dosage forms or delivery systems.